- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06775379
주요 우울증 장애에 대한 아제투칼너 대 위약의 무작위 연구 (X-NOVA2)
중등도에서 중증 주요 우울증 장애에 대한 아제투칼너를 평가하기 위한 3상, 무작위, 이중 맹검, 위약 대조, 다기관 연구
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
연구 개요
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85012
- IMA Clinical Research Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72211
- Woodland International Research Group
-
Rogers, Arkansas, 미국, 72758
- Woodland Research Northwest
-
-
California
-
Irvine, California, 미국, 92614
- Irvine Clinical Research
-
Los Angeles, California, 미국, 90025
- CalNeuro Research Group, Inc.
-
Oceanside, California, 미국, 92056
- Excell Research Inc.
-
Orange, California, 미국, 92866
- Atp Clinical Research
-
Orange, California, 미국, 92868
- Nrc Research Institute
-
Torrance, California, 미국, 90504
- CenExel CNS-TO (Collaborative Neuroscience Research)
-
Walnut Creek, California, 미국, 94596
- Sunwise Clinical Research
-
West Covina, California, 미국, 91790
- Kinetic Clinical Research, LLC
-
-
Connecticut
-
Cromwell, Connecticut, 미국, 06416
- Ct Clinical Research Associates
-
-
Florida
-
Coral Springs, Florida, 미국, 33067
- CNS Clinical Research Group
-
Hialeah, Florida, 미국, 33016
- NeoClinical Research
-
Jacksonville, Florida, 미국, 32256
- Clinical Neuroscience Solutions, LLC
-
Lakeland, Florida, 미국, 33803
- Accel Research Sites Lakeland
-
Largo, Florida, 미국, 33777
- Accel Research Sites - St. Petersburg-Largo
-
Miami, Florida, 미국, 33165
- PharmaSouth Research
-
Miami Beach, Florida, 미국, 33140
- Quantum Clinical Trials
-
North Miami Beach, Florida, 미국, 33162
- Harmony Clinical Research Inc
-
Orlando, Florida, 미국, 32801
- Clinical Neuroscience Solutions, LLC
-
Orlando, Florida, 미국, 32807
- Combined Research Orlando Phase I-Iv
-
Pensacola, Florida, 미국, 32503
- Panhandle Research and Medical Clinic
-
-
Georgia
-
Atlanta, Georgia, 미국, 30318
- Advanced Discovery Research
-
Atlanta, Georgia, 미국, 30328
- Synexus - Atlanta
-
Decatur, Georgia, 미국, 30030
- CenExel iResearch
-
Marietta, Georgia, 미국, 30060
- Psych Atlanta, Pc
-
Savannah, Georgia, 미국, 31405
- Cenexel Iresearch - Savannah
-
-
Idaho
-
Boise, Idaho, 미국, 83704
- Northwest Clinical Trials Inc
-
-
Illinois
-
Chicago, Illinois, 미국, 60634
- IMA Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02131
- Boston Clinical Trials Llc
-
Springfield, Massachusetts, 미국, 01103
- ELIXIA
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89102
- IMA Clinical Research Las Vegas
-
Las Vegas, Nevada, 미국, 89119
- Redbird Research
-
-
New York
-
Brooklyn, New York, 미국, 11229
- Integrative Clinical Trials
-
Staten Island, New York, 미국, 10314
- Richmond Behavioral Associates
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28211
- New Hope Clinical Research
-
-
Ohio
-
North Canton, Ohio, 미국, 44720
- Neuro-Behavioral Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73112
- Pahl Pharmaceutical Professionals Llc
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- Lehigh Center For Clinical Research
-
Philadelphia, Pennsylvania, 미국, 19104
- Adams Clinical - Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38119
- Clinical Neuroscience Solutions, LLC
-
-
Texas
-
Plano, Texas, 미국, 75024
- Delricht Research - Plano
-
Wichita Falls, Texas, 미국, 76309
- Grayline Research Center
-
-
Washington
-
Everett, Washington, 미국, 98201
- Core Clinical Research
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Adults ≥18 and ≤74 years of age and experienced their first major depressive episode (MDE) prior to 50 years of age
- Body Mass Index (BMI) ≤40 kg/m2
- Meets the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) criteria for current major depressive disorder and is currently in an MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI)
- Participant's current MDE has a duration of ≥6 weeks and ≤24 months.
Key Exclusion Criteria:
- Participant has a primary diagnosis of a mood disorder other than MDD.
- Participant has a history of any of the following: MDD with psychotic or catatonic features; MDD with mixed features; Bipolar I or II disorder; Obsessive-compulsive disorder; Schizophrenia, primary thought disorder, or other psychotic disorder.
- Participant has a current diagnosis of any of the following: MDD with seasonal pattern; Post traumatic stress disorder; Antisocial or borderline personality disorder (or presence of clinically significant borderline personality traits); Panic disorder and/or agoraphobia; ADHD treated with a psychostimulant, diagnosed during the current MDE, or with unstable symptoms, as judged by the investigator.
- Participant has a substance (excluding tobacco) or alcohol use disorder within the 12 months prior to screening.
- Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 2 years, or >1 suicide attempt >24 years of age.
- Participant has a history of non-suicidal self-harm behavior in the 12 months prior to screening.
- Participant has used antidepressants or other prohibited medications (including benzodiazepines), within the 2 weeks or within a period less than 5 times the drug's half-life, whichever is longer, prior to randomization.
- Participant has a history of non-response to ≥2 antidepressant drugs of adequate dose and duration in the current MDE as determined by the Antidepressant Treatment Response Questionnaire (ATRQ).
- Participants with medical conditions that may interfere with the purpose or conduct of the study
- Participant is pregnant, breastfeeding, or planning to become pregnant.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo |
Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks |
|
실험적: Azetukalner
Azetukalner 20 mg |
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6
기간: Baseline to Week 6
|
The HAMD-17 consists of 17 items that are used to rate the severity of depression symptoms. Each item is scored in a range of 0 to 2 points or 0 to 4 points, with higher scores indicating a greater degree of depression. The score for each item is summed to compute a total score, which ranges from 0 to 52 points. |
Baseline to Week 6
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
아제투칼너의 안전성과 내약성(예: 부작용)을 평가하기 위해
기간: 스크리닝(기준선 약 4주 전)부터 최종 투여 후 8주까지.
|
스크리닝(기준선 약 4주 전)부터 최종 투여 후 8주까지.
|
|
|
Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) score at Week 6
기간: Baseline to Week 6
|
The SHAPS is a 14-item self-report questionnaire used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater anhedonia. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are assigned a score of 1, while "strongly disagree" responses are assigned a score of 4 points. Total scores on the SHAPS can range from 14 to 56 points, with higher scores corresponding to higher levels of anhedonia. |
Baseline to Week 6
|
|
Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 1
기간: Baseline to Week 1
|
The HAMD-17 consists of 17 items that are used to rate the severity of depression symptoms. Each item is scored in a range of 0 to 2 points or 0 to 4 points, with higher scores indicating a greater degree of depression. The score for each item is summed to compute a total score, which ranges from 0 to 52 points. |
Baseline to Week 1
|
|
Change from baseline in the Clinical Global Impression of Severity (CGI-S) score at Week 6
기간: Baseline to Week 6
|
The CGI-S is a clinician-rated global measure of participant overall disease severity. Participants are rated on a 7-point severity scale, with higher scores indicating more severe depression. |
Baseline to Week 6
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .